Delivery Order SPE2DB24D2101-SPE2DB25FKNDJ
Award Date 8/6/25
Potential Completion Date 8/7/25
Potential Value $3.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $6,400.05, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This firm fixed-price delivery order, valued at $1,575.72, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The award was made on a...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 12, 2025, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a ceiling value of $11,239.33 under a firm fixed-price arrangement, with an ultimate completion date of September 15, 2025. The contract is funded through the Defense Logistics Agency's Medical Supply Chain, a defense-aligned federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,979.90 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL units, with an ultimate completion date of December 1, 2025. This non-competitive delivery order represents a firm fixed-price transaction under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be performed at the vendor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $11,270.93, represents a non-competitive award with an ultimate completion date of September 4, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable immunosuppressant medication used to treat autoimmune conditions. This competitively awarded, non-set-aside contract is valued at $8,875.49 with a firm fixed price structure and an ultimate completion date of September 10, 2025. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL pre-filled pens, with a contract ceiling value of $2,265.90. This is a firm fixed-price, competitively awarded delivery order issued without a set-aside designation, with an ultimate completion date of August 13, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...